METABOLIC & WEIGHT RESEARCH / FAQ
Questions From the Trial Record
Direct, citation-anchored answers to the questions readers most often bring to these three metabolic research peptides.
What is AOD-9604?
AOD-9604 is a synthetic 16-amino-acid fragment modeled on the C-terminal 'tail' region of human growth hormone (residues 176-191), with a tyrosine substituted for the natural phenylalanine at the front of the sequence. It does not bind the growth hormone receptor and is not itself growth hormone. It was developed as an oral anti-obesity drug candidate, tested in roughly six clinical trials involving about 900 obese adults [3], but its human obesity program did not demonstrate statistically significant weight loss versus placebo and was ultimately discontinued. It is not FDA-approved for any indication.
What does the peptide AOD9604 do?
In animal studies, AOD9604 reduced body fat and increased fat oxidation in obese mice, an effect linked to inhibition of an enzyme that builds new fat (acetyl-CoA carboxylase) and increased expression of beta-3 adrenergic receptors in fat tissue [4][5]. It was designed to reproduce only the fat-metabolizing action of growth hormone, without GH's growth-promoting or blood-sugar-raising effects. That rodent effect, however, did not translate into statistically significant human weight loss in the pivotal obesity trials [3]. Separately, in a preclinical rabbit model, intra-articular AOD9604 injections reduced cartilage-degeneration scores in an osteoarthritis model [1] — an unrelated line of research.
Does AOD-9604 actually work?
For weight loss in humans, the evidence says no — the pivotal human obesity trial program (roughly 900 subjects across about six studies) did not show statistically significant weight loss beyond placebo, and the compound's development as an obesity drug was discontinued [3]. It was, however, well tolerated, with a side-effect profile close to placebo [3], and its underlying rodent fat-metabolism mechanism was real and reproducible in mouse studies [4][5]. The gap between promising animal data and a negative human efficacy result is itself the most important thing to understand about this compound.
How does AOD-9604 work?
AOD-9604 is believed to act by inhibiting acetyl-CoA carboxylase, an enzyme involved in building new fat (lipogenesis), and by increasing expression of beta-3 adrenergic receptors in white adipose tissue, a receptor pathway tied to fat breakdown and energy expenditure. In mice lacking a functional beta-3 adrenergic receptor, AOD9604's chronic weight- and fat-reducing effect disappeared entirely, even though its acute fat-oxidation boost persisted — evidence that the chronic effect depends on that receptor pathway [4]. This mechanism has been demonstrated in rodents and cell models; it has not been shown to produce meaningful fat loss in humans [3].
What is tesamorelin?
Tesamorelin is a synthetic 44-amino-acid analogue of human growth hormone-releasing hormone (GHRH), modified with an N-terminal chemical group that resists rapid enzymatic breakdown. Rather than supplying growth hormone directly, it stimulates the pituitary gland to release more of the body's own GH. It is FDA-approved, specifically to reduce excess visceral fat in HIV-infected adults with lipodystrophy, and is given as a once-daily subcutaneous injection [7].
What does tesamorelin do?
Tesamorelin raises circulating growth hormone and, downstream, insulin-like growth factor-1 (IGF-1), which together promote fat breakdown preferentially in visceral (deep abdominal) fat. In clinical trials, it reduced visceral adipose tissue by roughly -27.71 cm2 on average across pooled studies, along with reductions in trunk fat and liver fat and an increase in lean body mass [6]. In a pivotal JAMA trial, it also reduced hepatic fat content by a net -2.9% over six months [8]. It does not directly target appetite or general body fat outside these specific measured effects.
How does tesamorelin work?
Tesamorelin binds the growth hormone-releasing hormone receptor on the pituitary gland's somatotroph cells, triggering a signaling cascade that causes those cells to release growth hormone in the body's natural pulsatile pattern. That GH then stimulates the liver to produce IGF-1; GH and IGF-1 together drive lipolysis, with a preference for visceral fat. A two-week study in healthy men confirmed tesamorelin measurably raises overnight GH and IGF-1 without significantly altering fasting glucose or insulin-stimulated glucose uptake over that period [9].
Will tesamorelin help me lose belly fat?
This site does not make individual predictions or recommendations. What the trial evidence shows is that tesamorelin, in randomized controlled trials of adults with HIV-associated lipodystrophy, produced statistically significant reductions in visceral (deep abdominal) fat — for example, a treatment effect of -42 cm2 in one pivotal trial [8] and a pooled -27.71 cm2 across five trials in a 2026 meta-analysis [6]. Its FDA approval is specifically for that population. Whether or how it would affect abdominal fat in someone outside that population is not something the published trial record answers, and it is not something this site can advise on.
What is tirzepatide?
Tirzepatide is a synthetic 39-amino-acid peptide that simultaneously activates two gut-hormone receptors — GIP (glucose-dependent insulinotropic polypeptide) and GLP-1 (glucagon-like peptide-1) — sometimes described as a 'twincretin.' It is FDA-approved for type 2 diabetes mellitus, chronic weight management, and moderate-to-severe obstructive sleep apnea in adults with obesity, given as a once-weekly subcutaneous injection [12].
How does tirzepatide work?
By engaging both the GIP and GLP-1 receptors, tirzepatide enhances glucose-dependent insulin secretion from the pancreas, suppresses glucagon release, and slows gastric emptying — mechanisms shared with single-receptor GLP-1 therapies but amplified by the added GIP engagement. In vitro work found tirzepatide favors the GIP receptor over the GLP-1 receptor and produces biased GLP-1-receptor signaling relative to the natural hormone [16]. In a direct 72-week head-to-head trial, this dual mechanism produced greater weight loss (-20.2%) than semaglutide (-13.7%) [11].
What does tirzepatide do in the body?
In the pancreas, tirzepatide increases glucose-dependent insulin release and suppresses glucagon, improving blood-sugar control. In the gut, it slows gastric emptying, extending fullness after meals — and contributing to the nausea some people experience. In the brain, it acts on appetite-regulating circuits to reduce hunger and food-seeking behavior, a mechanism reflected in patient reports of reduced 'food noise.' In its pivotal 72-week obesity trial, the highest dose (15 mg) produced a mean weight change of -20.9% versus -3.1% with placebo [14].
What is tirzepatide used for?
FDA-approved indications include type 2 diabetes mellitus, chronic weight management in adults with obesity or overweight plus a weight-related condition, and moderate-to-severe obstructive sleep apnea in adults with obesity. In clinical research, it has also been directly compared against semaglutide, both in type 2 diabetes (where it produced superior HbA1c reduction at every dose tested [15]) and in obesity (where it produced significantly greater weight loss over 72 weeks [11]).